We had a promising opportunity to secure a monopoly on S3, which could have resulted in an estimated annual profit of around $10 million. These numbers were based on the yearly presentation and commentary provided by Fresh Leaf Analytics' latest report. However, the unfortunate news of a failed trial changed the situation. I must acknowledge that @amb005 had valid concerns regarding the poor management and high debt the company possessed.
Considering the oversupplied global cannabis industry, if the market fails to sell CAN's indoor high-quality bud, I hate to sound pessimistic, but I am quite confident that the company will either go bankrupt or be acquired for a fraction of its current value. Of course, there is always a wild card possibility where New Zealand, Germany, or the US miraculously pass a bill to federally legalize cannabis. In that case, things could take a different turn
Good luck to everyone involved, and I extend my respect to AMB. Despite our heated debates and discussions in the past, I mean no disrespect. All the best with ECS, and I will be closely monitoring its progress. Who knows, if a lucrative opportunity presents itself, I might consider reentering the cannabis sector.
CAN Price at posting:
12.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)